Biomedical industry

In order to cultivate and develop biomedical industry clusters, the Shenzhen Municipal Development and Reform Commission, Shenzhen Municipal Science and Technology Innovation Commission, Shenzhen Municipal Industry and Information Technology Bureau, Shenzhen Municipal Administration for Market Regulation and the Shenzhen Municipal Health Commission have issued the "Shenzhen Action Plan for Cultivating and Developing Biomedical Industry Clusters (2022-2025)."

Development status:

The biomedical industry mainly includes biological medicine, chemical medicine, traditional Chinese medicine and natural medicine, and cell and gene products. In 2021, the business income of Shenzhen's biomedical industry reached 46.1 billion yuan; Seven Class I new drugs were approved for listing; 84 innovative drugs entered the clinical trial stage; 94 varieties passed the consistency evaluation of generic drugs; and the trend of simultaneously developing generic drugs and innovative drugs has gradually taken shape. Moreover, the industrial development agglomeration effect is prominent. Shenzhen High-Tech Park in Nanshan District and the national bio-industry base in Pingshan District have been set up to a preliminary level, and a number of innovation carriers such as Guangdong's small molecule new drug innovation center have developed rapidly.

Objectives:

(1) The industrial agglomeration effect will be significantly enhanced. By 2025, the added value of the biomedical industry will reach 40 billion yuan, while its operating income will hit 100 billion yuan. A number of professional biomedical industrial parks with distinctive characteristics and coordinated development will be built, and the level of industrial agglomeration will be significantly improved.

(2) The industrial structure will be continuously optimized. Shenzhen will attract 8-10 enterprises with global influence to set up their headquarters, R&D centers, and high-value-added production bases. The city will have 40 bio-medicine enterprises listed on Chinese and overseas stock markets, five enterprises each with revenue of more than 10 billion yuan, 15 enterprises with revenue of more than 1 billion yuan apiece, and 25 enterprises with revenue in excess of 100 million yuan.

The scientific and technological innovation capacity will be greatly improved. R&D investment by enterprises above the designated size will reach 10%. At the same time, 200 innovation carriers of all types at all levels will be built, along with five key pieces of scientific and technological infrastructure. A series of major platforms will be built including those for model experimental animal research, pharmaceutical CRO/CDMO/CMO, biological product inspection and detection, and the internationalization of traditional Chinese medicine and natural products. The city will obtain 15 approval documents for domestic Class I new drugs to enter the market, and 400 drugs will enter the clinical trial stage.